Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Cardiol. 2006 May 15;97(10):1515-8. Epub 2006 Mar 29.

Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy.

Author information

1
Institut für Röntgendiagnostik, Würzburg, Germany. beer@roentgen.uni-wuerzburg.de

Abstract

The present study evaluated the evolution of cardiac morphology, function, and late enhancement as a noninvasive marker of myocardial fibrosis, and their inter-relation during enzyme replacement therapy in patients with Fabry's disease using magnetic resonance imaging and color Doppler myocardial imaging. Late enhancement, which was present in up to 50% of patients, was associated with increased left ventricular mass, the failure of a significant regression of hypertrophy during enzyme replacement therapy, and worse segmental myocardial function. Late enhancement may predict the effect of enzyme replacement therapy on left ventricular mass and cardiac function.

PMID:
16679096
DOI:
10.1016/j.amjcard.2005.11.087
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center